ATE555793T1 - REDUCING THE SIDE EFFECTS OF AROMATASE INHIBITORS USED IN THE TREATMENT OF BREAST CANCER - Google Patents
REDUCING THE SIDE EFFECTS OF AROMATASE INHIBITORS USED IN THE TREATMENT OF BREAST CANCERInfo
- Publication number
- ATE555793T1 ATE555793T1 AT06804410T AT06804410T ATE555793T1 AT E555793 T1 ATE555793 T1 AT E555793T1 AT 06804410 T AT06804410 T AT 06804410T AT 06804410 T AT06804410 T AT 06804410T AT E555793 T1 ATE555793 T1 AT E555793T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- breast cancer
- side effects
- reducing
- aromatase inhibitors
- Prior art date
Links
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 229940046844 aromatase inhibitors Drugs 0.000 title 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed is the use of an androgenic agent in the preparation of a pharmaceutical composition for use in improving one or more side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer and having received treatment with an aromatase inhibitor.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005905768A AU2005905768A0 (en) | 2005-10-19 | Therapeutic methods, compositions and kits | |
| US73266205P | 2005-11-03 | 2005-11-03 | |
| US79830806P | 2006-05-08 | 2006-05-08 | |
| PCT/AU2006/001539 WO2007045027A1 (en) | 2005-10-19 | 2006-10-18 | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE555793T1 true ATE555793T1 (en) | 2012-05-15 |
Family
ID=40214740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06804410T ATE555793T1 (en) | 2005-10-19 | 2006-10-18 | REDUCING THE SIDE EFFECTS OF AROMATASE INHIBITORS USED IN THE TREATMENT OF BREAST CANCER |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN101340914B (en) |
| AT (1) | ATE555793T1 (en) |
| NZ (1) | NZ567816A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113967217A (en) * | 2021-12-10 | 2022-01-25 | 山东山大附属生殖医院有限公司 | Application of letrozole and testosterone undecanoate in treatment of asthenospermia |
-
2006
- 2006-10-18 AT AT06804410T patent/ATE555793T1/en active
- 2006-10-18 NZ NZ567816A patent/NZ567816A/en not_active IP Right Cessation
- 2006-10-18 CN CN2006800478163A patent/CN101340914B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101340914A (en) | 2009-01-07 |
| NZ567816A (en) | 2011-08-26 |
| CN101340914B (en) | 2011-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2010000209A1 (en) | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
| MX349787B (en) | Oral dosage forms including an antiplatelet agent and an acid inhibitor. | |
| TW200501960A (en) | Synergistic kits and compositions for treating cancer | |
| AU2016204344A1 (en) | Improved methods and compositions for wound healing | |
| MX2010010300A (en) | Mtor inhibitor salt forms. | |
| NO20092637L (en) | Methods of treatment | |
| ATE553198T1 (en) | TREATMENT OF CANCER THROUGH THE COMBINED INHIBITION OF PROTEASOME AND TELOMERASE ACTIVITIES | |
| EA200870019A1 (en) | LACTAMIC CONNECTIONS AND METHODS OF THEIR APPLICATION | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| PH12014500053A1 (en) | Proteasome inhibitors | |
| MX2011006685A (en) | Membrane type-1 matrix metalloprotein inhibitors and uses thereof. | |
| UA95310C2 (en) | Composition containing chkl inhibitor and cyclodextrin for the treatment of cancer | |
| MX2007016322A (en) | Compositions and methods for the diagnosis and treatment of tumor. | |
| NO20060398L (en) | Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for the treatment and inhibition of cancer | |
| IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
| ATE456571T1 (en) | PROTEASOME INHIBITORS AND METHODS OF USE THEREOF | |
| MX2007011545A (en) | Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors. | |
| EA200800755A1 (en) | IKK INHIBITORS INTRODUCED FOR THE TREATMENT OF ENDOMETRIOSIS | |
| DE602005026866D1 (en) | USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | |
| UA94922C2 (en) | Method for controlling tissue factor signaling specificity in a mammalian subject, method for identifying an agent which specifically inhibits tissue factor signaling | |
| MX2009005550A (en) | Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy. | |
| BRPI0511475A (en) | combination, pharmaceutical composition, use of a combination, and method for treating cancer | |
| EA200800766A1 (en) | PI3K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | |
| DK2041181T3 (en) | Specific protease inhibitors and their use in cancer therapy | |
| ATE555793T1 (en) | REDUCING THE SIDE EFFECTS OF AROMATASE INHIBITORS USED IN THE TREATMENT OF BREAST CANCER |